In November 2017 Cancer52 responded to the NICE Centre for Health Technology Evaluation consultation entitled “Increasing capacity within Technology Appraisals“.
Whilst we of course share the desire for earler and faster appraisal for new medicines our response focused on the seeming drop in levels of patient engagement in the HTA process and in the consultation process itself. There will we understand be a second round of consultation in January 2018, and a speaker from NICE invited to our All Member Meeting on 24th January 2018 to explain the process.
Cancer52’s full response can be read here.